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In order to correlate a characteristic clinical pheno­
type with biochemical abnormalities in recessive dys­
trophic epidermolysis bullosa, fibroblast cultures were 
established from 4 typical patients with the severe form 
of the disease. Collagenase, the enzyme implicated in the 
pathogenesis of blistering, was present in vitro in 2- to 
4-fold greater concentrations than in control fibroblast 
cultures. Partially purified preparations of this enzyme 
displayed marked thermal lability and diminished affin­
ity for Ca2+, a metal cofactor, suggesting the existence of 
a mutant enzyme. The data suggest that these 3 biochem­
ical abnormalities, increased synthesis, decreased ther­
mal stability and diminished affinity for Ca2+, should 
serve as reliable in vitro markers for genetic discrimi­
nation of recessive dystrophic epidermolysis bullosa. 
Hecessive dystrophic epidermolysis bullosa (RDEB) is a he­
reditary disease characterized by trauma-induced blistering of 
the skin and mucosal surfaces which results in scarring, milium 
formation, nail dystrophy, mitten-like deformities resulting 
from protein loss through the skin [1, 2]. Morphologic studies 
at the ultrastructural level have indicated an association of the 
blistering process with collagen destruction in the papillary 
dermis [3-6], suggesting a protease-mediated process. Subse­
quent in vivo [7,8] and in vitro [9-11] investigations established 
that human skin collagenase-the enzyme that initiates colla­
gen degradation in the skin [12]-is synthesized in substantially 
increased amounts by skin fibroblasts [10, 11]. However, at 
least one aspect of the potential pathogenic relationship be­
tween increased collagenase and clinical phenotype in this 
disease remains in question, i.e., the possibility of genetic het­
erogeneity. 
In recapitulating the history of the studies on collagenase in 
RDEB, the data clearly indicate variability in collagenase 
expression. For example, in the initial in vitro investigation, 
Eisen showed that, while whole organ cultures of unaffected 
RDEB skin displayed increased collagenase activity, the levels 
ranged from only slightly increased to 4-fold increased [9]. In 
contrast, in a second series of experiments in a different labo­
ratory, collagenase activity in organ cultures was not found to 
be elevated at all [13]. In order to resolve this apparent dispar­
ity, we measured immunoreactive collagenase in tissue extracts 
of normal-appearing skin [7]. Although we demonstrated a 
mean 4-fold elevation in immunoreactive collagenase in the 
skin, providing strong evidence for a pathogenic role for the 
enzyme, the range of values varied from 1.3- to 12-fold increased 
[7]. Thus, these in vivo data also suggested the possibility of 
genetic heterogeneity. 
We next reasoned that a cell culture system might help to 
elucidate the nature of this issue, since, if collagenase were 
indeed a pathogenically important, genetically specific enzyme 
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in RDEB, it should be synthesized in increased amounts in 
fibroblast cultures [10]. Eight out of the 10 RDEB fibroblast 
strains examined (each from a different patient) displayed 
increased collagenase in culture. In contrast, none of the fibro­
blast strains isolated from other types of EB-recessive junc­
tional EB, dominant dystrophic EB or dominant EB simplex­
displayed increased collagenase [10]. Since elevated in vitro 
synthesis of collagenase served as a biochemical marker for 
RDEB in 8 out of 10 cases, one possibility for the failure to 
observe complete agreement between the clinical and biochem­
ical data was again, that they were reflective of genetic heter­
ogeneity in the disease. 
To help resolve whether heterogeneity exists, one approach 
would be to correlate the in vivo and in vitro aberrations in 
collagenase as closely as possible with the specific clinical 
picture to ascertain the degree of association and to assess the 
potential usefulness of these biochemical markers. For this 
purpose, we have examined not only the synthesis of collagenase 
but also have sought evidence for a structurally abnormal form 
of the enzyme [14, 15]. The purpose of this report is to present 
the investigations on 4 patients with RDEB whose clinical 
characteristics will be detailed. Such information should pro­
vide dermatologists and geneticists with a representative pic­
ture of the biochemical abnormalities in collagenase as they 
relate to a specific clinical phenotype in RDEB. 
METHODS 
Fibroblast Cultures 
RDEB fibroblast cultures were established from a 3-mm skin punch 
biopsy after obtaining informed consent. Control cultures were initiated 
from healthy volunteers or were purchased from The American Type 
Cell Collection, Rockville, Md. Cells were grown in plastic culture flasks 
(Corning Glass Works, Science Products Div., Corning, N.Y.) in Dul­
becco's modified Eagle's medium-high glucose + glutamine (Microbio­
logical Associates, Walkersville, Md.) with 0.03 M N-2-hydroxyethylpi­
perazine-N'-2-ethanesulfonic acid (Hepes) buffer (pH 7.6), 20% fetal 
calf serum, and 200 U of penicillin and 200 fl.g of streptomycin per ml at 
37°C. In experiments to determine the concentration of collagenase in 
the culture medium, fibroblasts were grown under ideal conditions of 
cell density [16] and pH [17]. Serum-containing medium was then 
removed, the cells were washed 4 times with Hank's balanced salt 
solution, and the cultures were maintained in serum-free Dulbecco's 
modified Eagle's medium-HG + glutamine for 24 hours. This serum­
free medium was then stored at -80°C until assayed for collagenase 
activity and immunoreactive enzyme protein. 
Collagenase Assay 
Human skin pro collagenase was activated proteolytically with tryp­
sin as described previously [18]. For each enzyme preparation, a range 
of trypsin concentrations (0.1-2.0 fl.g trypsin per 50 fl.l enzyme sample) 
was employed to ensure that maximal collagenase activity was meas­
ured. After preincubation with trypsin for 10 min at 25°C, at least a 5-
fold molar excess of soybean trypsin inhibitor was added to inhibit 
further trypsin activity. Each mixture was then assayed for collagenase 
activity at 37°C in 0.05 M Tris-HCl (pH 7.5) in the presence of 10 mM 
CaClz using native, reconstituted [14C] glycine-labeled collagen fibrils 
containing approximately 4,000 cpm per substrate gel [19]. 
Radioimmunoassay of Human Skin Collagenase 
Immunoreactive human skin collagenase was measured by a slight 
modification of the double antibody radioimmunoassay previously re­
ported [20]. The pro collagenase used as the unlabeled standard and for 
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iodination in the radioimmunoassay was purified to homogeneity from 
celt culture medium as described by Stricklin et al [21]. This same 
enzyme preparation was used to produce functionally specific antiserum 
to the enzyme [22]. Standard radioimmunoassay curves were derived 
from duplicate reactions performed in disposable plastic microfuge 
tuhes (Beckman Instruments, Inc., Fullerton, Calif.) that contained a 
1:2,500 dilution of the gamma globulin fraction of antiserum to human 
skin collagenase, l""I-labeled human skin collagenase (approximately 
20,000 cpm/tube) and 0-100 ng of electrophoretically homogeneous 
human skin collagenase in a total vol of 250 fll. After incubation for 24 
hr at 4 ° C , goat anti-rabbit IgG was added in excess. The resulting 
precipitates were isolated, washed, and counted in a single channel 
gamma scintillation spectrometer. Unknowns, consisting of the various 
collagenase preparations, were assayed for immunoreactive enzyme 
protein in an identical fashion using 100-fll portions of serial doubling 
dilutions of the enzymes. Controls in which nonimmune rabbit gamma 
glohulin was substituted for specific antiserum were routinely included. 
Partial Purification of Collagenase 
For partial purification of the RDEB and control procollagenases, 
fibroblasts were subcultivated in large glass roller bottles (1585 cm"). 
At confluence (5-10 x 10· cells per roller bottle), the cells were put 
through several cycles of serum-free medium for 24-48 hr [181- The 
crude, serum-free medium was concentrated about lO-fold by vacuum 
dialysis and stored at -70°C until a sufficient quantity had been 
accumulated for partial purification [14]. This crude medium was then 
dialyzed against the appropriate starting buffer for purification by 
cation exchange chromatography employing either phospho cellulose or 
carboxymethylcellulose, as described by Stricklin et al [21). Enzyme­
containing fractions were pooled, dialyzed into 50 mM Tris-HCI buffer 
(pH 7.5) containing 10 mM CaClc, and stored in small aliquots at -70°C 
until used. 
Thermal Stability of Procollagenase 
Since CaH is both essential for activity and is a thermo stabilizer of 
collagenase [23] thermal activation of procollagenases from abnormal 
and HDEB cells was determined by removing extrinsic Ca" by dialysis 
against at least 4,000 volumes of 50 mM Tris-HClIO.15 M NaCI buffer 
for 18 hr, after which Ca"+ was restored in varying concentrations, and 
thl." preparations were heated at 60°C for various times (0-5 min). After 
this incubation, the enzyme preparations were placed on ice for 10-15 
min and then assayed for residual collagenase activity as described 
above. Control and RDEB collagenases were always examined simul­
taneously. [141-
Affinity of RDEB Collagenase for Ca"+ 
To assess the extrinsic metal cofactor requirements of the RDEB 
collagenases, Cau was removed from the partially purified enzyme 
preparations by dialysis against 50 mM Tris-HCI/0.15M NaCI buffer for 
18 hr at 4°C [141- For kinetic analysis, Cac+ was replaced in varying 
concentrations prior to enzyme assay [14). The apparent K", for Ca" 
was determined from double-reciprocal plots using a programmable 
calculator. 
Other Assays 
Protein was determined by the method of Lowry et al [24] with a 
bovine serum albumin standard. Statistical analysis was performed by 
Student's t-test. 
RESULTS 
The clinical and ultrastructural morphologies of these 4 
patients were absolutely typical of those of patients with mod­
erately severe and severe RDEB (Table I). In each case, blis­
tering was widespread, and the patients had experienced nu­
merous complications of the disease . The extent of involvement 
in each patient can be appreciated best from the representative 
clinical photographs (Fig 1-4). 
To gain insight into the pathogenic role of collagenase in the 
blistering and soft tissue destruction which characterizes 
RDEB, we measured the capacity of their skin fibroblasts to 
synthesize collagenase (Table II). For these pxperiments , biop­
sies were taken from normal-appearing skin for initiating the 
cell cultures, and the cells were used between passages 3 and 
1:3. With each cell strain, there was a 2- to 4-fold increase in the 
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TABLE 1. Clinical characteristics of the RDEB patients" 
Clinical trait Patient 1 Patient 2 Patient 3 Patient 4 
----_ . 
Sex, age F,12 F,3 M,4 M,4 
Onset of blistering birth birth birth birth 
Distribution generalized generalized generalized generalized 
Overall severity +++ ++++ ++++ ++++ 
Scars, milia ++-+ ++++ ++++ ++++ 
N ail dystrophy +++ ++++ ++++ ++++ 
Acquired syndac- feet only hands, feet hands, feet hands, feet 
tyly 
Flexural contrae- + +++ +++ +++ 
tures 
Mucosal Lesions +++ ++++ ++++ ++++ 
Dysplastic teeth ++ +++ +++ ++++ 
Growth retarda- no yes yes yes 
tion 
height <5th %-ile <5th %-ile <5th %-ile 
weight <.5th %-ile <5th %-ile <5th %-ile 
Anemia ++ +++ + +++ 
Ultrastructural Dermolytic Dermolytic Dermolytic Dermolytic 
pattern 
" The severity of the various trait...;; estimated in a semiquantitative manner + 
mild; ++ mild to moderate; +++ moderate to severe; ++++ severe. 
J<"IG 1. Clinical photograph of Patient 1. The patient is a 12-yr-old 
female with an overall severity of a+. 
FIG 2. Clinical photograph of Patient 2. The patient is a a-yr-old 
female with an overall severity of 4+. 
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FIG 3. Clinical photograph of Patient 3. The patient is a 4-yr-old 
male with an overall severity of 4+. 
FIG 4. Clinical photograph of Patient 4. The patient is a 4-yr-old 
male with an overall severity of 4+. 
TABLE II. Accumulation of immunoreactive human skin 
collagenase in RDEB fibroblast cultures" 
Patient 
1 
2 
3 
4 
Culture 
designation/! 
WUE 7506 
WUE 7565 
WUE 76108 
WUE 76114 
No. of 
Cultures' 
8 
7 
13 
7 
Imnlunoreaetive 
eollagenase/mg protein 
'X of Control 
234 ± 43 
188 ± 43 
340 ± 92 
424 ± 76 
" Immunoreactive collagenase was quantitated by radioimmunoassay 
as ng/mg cell protein, and the data are expressed as a % of the amount 
found in control cultures in the same experiments [101. The HDEB 
values were statistically higher than the controls at p < 0.01 (WUE 
7506), p < 0.025 (WUE 7565), p < 0.05 (WUE 76108), and p < 0.001 
(WUE 76114). Adapted from reference 10. 
b Culture designation refers to cell strains used in reference 10. 
'Number of cultures examined for eacb strain. 
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TABLE III. Properties of the RDRB procollagenases" 
Thermal stability 
Culture Patient designation ('ii. loss of activity after 
5 min at 60°C) 
Control lWEB 
1 WUE 7506 10 43 
2 WUE 7565 10 50 
3 WUE 76108 0 35 
4 WUE 76114 3 53 
A-pparent Kill for C£l�l 
----
(mM) 
Control RDEli 
0.95 4.60 
0.95 2.75 
1.33 :3.92 
1.06 3.49 
"The thermal stability and cofactor kinetics for each proenzyme 
preparation were determined as detailed in "Methods." The values for 
patients 1 and 2 are derived from the data presented in reference 14. 
The values for patient 4 are derived from reference 15. 
accumulation of immunoreactive collagenase in the culture 
medium during a 24-hr period [10]. This increase in immuno­
reactive material was also reflected by an increase in trypsin­
activatable enzyme activity in the medium [10]. In one case 
(patient 4, cell strain WUE 76114), we also examined the in 
vivo levels of immunoreactive collagenase [7]. In this patient, 
tissue levels of collagenase were 384% of control, a value closely 
reflected by the amount of collagenase seen in his cell cultures 
(i.e., 424±76% of control), thus lending additional support for a 
pathogenic role for this enzyme in RDEB. 
It should be emphasized that the enhanced synthesis of 
collagenase was apparently a specific manifestation of the 
RDEB fibroblasts, since neither total protein synthesis nor the 
growth kinetics of these cells was altered [10]. Furthermore, the 
activities of typical cytoplasmic (lactic dehydrogenase) and 
lysosomal (,B-glucuronidase) enzymes were determined in fibro­
blast cultures of patient 4 (WUE 7506) and were found to be 
unaltered when compared to the control cell strains [10 J. 
We have also sought further evidence for a close genetic and 
pathophysiologic role for collagenase in HDEB by examining 
some of the properties of the enzyme [14, 15]. Here, we utilized 
partially purified enzyme preparations to examine the thermal 
stability of the proenzyme as a probe to detect an aberration in 
structure. As shown in Table III, both the procollagenases from 
the 2 patients we initially reported (patients 1 and 2) [14J and 
those from 2 additional patients (patients 3 and 4) displayed a 
significant reduction in thermal stability. Since Ca"; functions 
as a thermal stabilizing metal cofactor for collagenase (2:3), it 
seemed reasonable that these decreases in stability might reflect 
an altered affinity of the putatively mutant enzymes for Ca"-+ 
[14]. Indeed, the pro collagenase derived from each patient's cell 
cultures displayed a significant increase in the apparent K,,, for 
Ca2+, with valves ranging from 3 to 5 times higher than those 
found in the control enzyme preparations (Table III). Thus, 
both the thermal stability and the cofactor kinetic data suggest 
the existence of a mutant form of collagenase in these typical 
patients with RDEB [14, 15]. 
DISCUSSION 
Recessive dystrophic epidermolysis bullosa exists within a 
clinical spectrum varying in severity from the highly typical, 
severe patients discussed in this report to those with localized 
disease involving only major sites of trauma [1, 2]. However, 
this disease designation also encompasses patients with an 
"inverse" distribution of lesions, whose ultrastructural pathol­
ogy is the same but whose clinical pattern speaks for further 
genetic heterogeneity [6]. Because of this variable clinical 
expression of RDEB and because we have observed variable 
expression of collagenase in HDEB, in this paper we have 
attempted to correlate the biochemical changes with a specific 
clinical phenotype. Each of these 4 patients was both clinically 
and histologically typical of severe HDEB (Table I, Fig 1-4). In 
association with this phenotype, the fibroblast cultures dis­
played a characteristic triad of biochemical abnormalities in 
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collagenase: increased synthesis, decreased thermal stability, 
and decreased affinity for Ca2+ (Tables II, III). 
It should be emphasized that each patient was from a differ­
ent kindred, thus arguing for a strong association of these 
abnormalities in collagenase with RDEB of their particular 
phenotype. The implications of this association are twofold. 
First, the 3 abnormalities in collagenase expression would ap­
pear to represent a set of reliable in vitro biochemical markers 
for discriminating RDEB and may prove to be useful for 
antenatal diagnosis and carrier detection. Second, it is equally 
important to recognize that these markers may be useful for 
defining biochemically a genetic heterogeneity within the spec­
trum of RDEB, such as others have speculated exists on the 
basis of clinical phenotype (e.g., in patients with "inverse" 
RDEB) [6]. This aspect is especially important, since the find­
ing of overproduction of a specific protein does not fit the usual 
pattern of recessive disease. Nevertheless, examples of heredi­
tary disorders with increased synthesis of an abnormal gene 
product exist [25-29]. In common with those disorders, our 
studies in RDEB show the co-existence of increased synthesis 
of collagenase [11] with a structurally abnormal form of the 
enzyme [14, 15]. These data would, thus, lead us to the intri­
guing speculation that the mutation involving collagenase in 
this disease is affecting both structural and regulatory portions 
of the gene. 
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